Brief: Argenx Q3 Total Operating Income $589 MLN
Oct 31 (Reuters) - argenx SE ARGX.BR :
* Q3 TOTAL OPERATING INCOME $ 589 MLN
* PHASE 1 STUDIES OF ARGX-213 AND ARGX-121 EXPECTED TO START
IN
SECOND HALF OF 2025
* INVESTIGATIONAL NEW DRUG (IND) APPLICATIONS FOR ARGX-220
AND
ARGX-109 ON TRACK TO BE FILED BY END OF 2025
Source text: ID:nGNE9PMWGJ
Further company coverage: ARGX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles